Peptides and proteins have a wide range of therapeutic uses. These options come, however, with their own advantages and limitations, which must be identified before selecting the right treatment.
In an article published in European Biopharmaceutical Review, Maria Chen, VP of Business Development, and Haishan Jang, CEO, discuss how we can overcome drug development challenges to provide affordable peptide and protein treatments.
Read the article to find out more.
This article is taken from European Biopharmaceutical Review April 2022, pages 52-53. © Samedan Ltd.
